ACTRN12612001093875尚未招募2 期
A Phase 2, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the safety and Efficacy of RT001 Gel for the Treatment of Allergic Rhinitis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Seasonal allergic rhinitis reactive to rye grass allergen on skin prick test
- •Total nasal symptom score of at least 7 (scale 0-12)
排除标准
- •Nasal disease such as sinusitis, polyps, or nasal structural abnormalities likely to affect application of medication
- •Bacterial or viral infection within 14 days of screening
- •Nasal surgery within 1 year
- •Active asthma requiring medication more than 3 times per week or significant pulmonary disease within 1 year
- •Frequent use of high doses of anti-inflammatory drugs within 2 weeks of treatment or antibiotics within 4 weeks
- •Current use of aminoglycoside or other agents that might interfere with neuromuscular transmission
- •Previous treatment with botulinum toxin or history of botulism
- •Neurological condition that might place subject at increased risk with exposure to Botulinum Toxin Type A
研究者
相似试验
进行中（未招募）
不适用
Combination treatment of antidepressant medication with eye training program to treat lazy eye in adultstreatment of adult amblyopia - amblyopia due to myopic or hyperopic anisometropia, or, congenital esotropiaMedDRA version: 15.0Level: LLTClassification code 10065008Term: Amblyopia unilateralSystem Organ Class: 10015919 - Eye disordersMedDRA version: 15.0Level: PTClassification code 10001906Term: AmblyopiaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 15.0Level: LLTClassification code 10042158Term: Strabismic amblyopiaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 15.0Level: LLTClassification code 10015475Term: EsotropiaSystem Organ Class: 10015919 - Eye disordersEUCTR2010-023216-14-EEHermo Pharma Ltd34
进行中（未招募）
不适用
Combination treatment of antidepressant medication with eye training program to treat lazy eye in adults.treatment of adult amblyopia - amblyopia due to myopic or hyperopic anisometropia, or, congenital esotropia.MedDRA version: 14.1Level: LLTClassification code 10065008Term: Amblyopia unilateralSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10015475Term: EsotropiaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10042158Term: Strabismic amblyopiaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10001906Term: AmblyopiaSystem Organ Class: 10015919 - Eye disordersEUCTR2010-023216-14-FIHermo Pharma Ltd
进行中（未招募）
1 期
A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of IntracoronaryAdministration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart FailureEUCTR2012-001700-37-HUCelladon Corporation250
进行中（未招募）
不适用
A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart FailureModerate to advanced heart failure (NYHA class II, III or IV) due to systolic dysfunctionMedDRA version: 18.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849EUCTR2012-001700-37-PLCelladon Corporation250
进行中（未招募）
不适用
A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart FailureModerate to advanced heart failure (NYHA class II, III or IV) due to systolic dysfunctionMedDRA version: 18.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849EUCTR2012-001700-37-BECelladon Corporation250